Veterinary Pharmaceuticals Market Report 2026

The veterinary pharmaceuticals market size has grown strongly in recent years. It will grow from $34.92 billion in 2025 to $37.01 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to increasing prevalence of animal diseases, rising livestock population, growth in companion animals, government regulations supporting animal health, advancements in veterinary research.

The veterinary pharmaceuticals market size is expected to see strong growth in the next few years. It will grow to $46.88 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to emerging biopharmaceutical technologies, increasing r&d in veterinary drugs, adoption of precision medicine for animals, growth in preventive veterinary healthcare, rising investments in companion animal pharmaceuticals. Major trends in the forecast period include development of novel veterinary drugs, growth of companion animal healthcare, rising use of combination therapies, expansion of oral and topical formulations, emphasis on rapid metabolism and bioavailability.

The rising pet ownership is expected to drive the growth of the veterinary pharmaceuticals market in the coming years. Pet ownership refers to the legal and ethical responsibility of individuals or households to care for, maintain, and ensure the well-being of domesticated animals, commonly known as pets. This trend is increasing as people seek companionship and emotional support. Growing pet ownership fuels higher demand for veterinary care, which in turn stimulates the veterinary pharmaceuticals market by expanding the need for medications, vaccines, and preventive treatments essential for maintaining the health of a larger and more diverse population of companion animals. For example, in April 2025, according to the Canadian Animal Health Institute, a Canada-based trade association, Canada was home to an estimated 7.2 million dogs and 8.2 million cats in 2024, making pets a key part of over half of Canadian households. Therefore, increasing pet ownership is supporting the growth of the veterinary pharmaceuticals market.

Key players in the veterinary pharmaceuticals market are developing new products, such as molidustat oral suspensions, to reach larger customer bases, increase sales, and boost revenue. Molidustat oral suspension is a medication used to manage nonregenerative anemia associated with chronic kidney disease (CKD) in cats. For instance, in September 2023, Elanco Animal Health Incorporated, a US-based pharmaceutical company, launched Varenzin-CA1 (molidustat oral suspension), the first and only therapy approved to treat non-regenerative anemia in cats with CKD, receiving provisional approval from the U.S. Food and Drug Administration (FDA). Varenzin-CA1 is notable for being a needle-free oral suspension that can be administered at home without in-clinic injections. It is also the first cat medication to receive expanded conditional approval, a pathway designed to accelerate the development of innovative therapies and provide treatment options for animals with rare, serious, or life-threatening conditions, or for illnesses lacking effective existing therapies.

In April 2025, Swedencare AB (publ), a Sweden-based provider of animal health and wellness products, including pharmaceuticals, supplements, and specialty veterinary formulations for companion animals, acquired Summit Veterinary Pharmaceuticals Limited for approximately $38 million (£30 million). Through this acquisition, Swedencare aimed to strengthen its veterinary pharmaceuticals portfolio and expand its presence in the UK and Hong Kong markets by integrating Summit’s established specialty pharma business, enhancing product offerings for veterinary professionals and broadening its geographic footprint in key growth regions. Summit Veterinary Pharmaceuticals Limited, based in the UK, develops, manufactures, and sells customized specialty veterinary pharmaceutical products exclusively for veterinary professionals in the UK and Hong Kong.

Major companies operating in the veterinary pharmaceuticals market are Zoetis Inc, Merck & Co. Inc, Boehringer Ingelheim International Gmb, Elanco Animal Health Incorporated, Ceva Sante Animale, Virbac SA, Dechra Pharmaceuticals PLC, Vetoquinol S.A., Phibro Animal Health Corporation, Kyoritsu Seiyaku Corporation, Hebei Chengshengtang Animal Pharmaceutical, Shijiazhuang Fengqiang Animal Pharmaceutical Co.Ltd, Vvaan Lifesciences Private Limited, Century Pharmaceuticals Limited, Cargill India Pvt. Ltd., Jurox Pty Ltd, Bayer, Veteq, Nimrod Veterinary Products Ltd., Bimeda, Orion Animal Health, Petmedix, Eco Animal Health, Teknofarma, Farmavet, Candioli Pharma, Suanfarma, Marino Ibericamed, MPA veterinary, Swetrade Pharmaceuticals AB, Animalcare, VET-AGRO Sp. z o. o, CANPOLAND SA, Cymedica, VIC Group, NITA-FARM, Apicenna LLC, Delos Medica, Provet Group, Bioveta AS, Veterinarski Zavod Subotica, PharmaGal s.r.o., Trifecta Pharmaceuticals USA LLC., Alberta Veterinary Laboratories Ltd., Veterinary Purchasing Co. Ltd, UCBVET, Syntec, Sauvet, Vetanco, Chemo Argentina, Brouwer, Agrovet Market Animal Health, Lemavet, Primo Veterinary Medicines Trading LLC., AL Kubara Veterinary Medicines Trading LLC., Eurovets Veterinary Suppliers, Saudi Pharmaceutical Industries, DBK Pharma S.A.E., Dawa Limited, Neimeth International Pharmaceuticals, Osy-Adamu Pharmaceutical Co., Global Vet (U) Ltd.

North America was the largest region in the veterinary pharmaceuticals market in 2025. Asia-Pacific was the second-largest region in the global veterinary pharmaceuticals market report. The regions covered in the veterinary pharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the veterinary pharmaceuticals market by increasing costs for imported antibiotics, vaccines, and parasiticides, particularly in asia-pacific and europe, where dependence on foreign manufacturing is high. The increased costs have affected veterinary hospitals, clinics, and pharmacies, slowing procurement of certain high-end drugs. However, tariffs have also encouraged local production and innovation, enabling domestic manufacturers to develop cost-effective alternatives and strengthen regional supply chains, which may enhance long-term market resilience.

The veterinary pharmaceuticals market research report is one of a series of new reports that provides veterinary pharmaceuticals market statistics, including veterinary pharmaceuticals industry global market size, regional shares, competitors with a veterinary pharmaceuticals market share, detailed veterinary pharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary pharmaceuticals industry. This veterinary pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Veterinary pharmaceuticals constitute a category of pharmacologically active drugs employed to control, prevent, and treat diseases in animals. These drugs exhibit their effects upon administration to animals and undergo rapid breakdown into active ingredients, primarily facilitated by small intestine metabolism.

The primary types of veterinary pharmaceuticals encompass veterinary vaccines, veterinary antibiotics, veterinary parasiticides, and other varieties. Veterinary vaccines offer protection against one or more diseases, mitigating their severity or preventing them altogether. The routes of administration include oral and various other routes tailored to different animal types, including companion animals and livestock. The vaccines themselves are classified into categories such as inactivated vaccines, attenuated vaccines, recombinant vaccines, and others, and they are supplied by diverse end-users, including veterinary hospitals, veterinary clinics, pharmacies, and drug stores.

The veterinary pharmaceuticals market consists of sales of biological drugs, biosimilars, monoclonal antibodies, sedatives, and antihistaminic. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.